Real-world study of deucravacitinib for plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have moderate to severe plaque psoriasis diagnosed by a doctor
- You are about to start deucravacitinib for the first time
- You agree to participate in the study
- You are not currently in or planning to join another interventional clinical trial
- You have never taken deucravacitinib before, including in a blinded study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well deucravacitinib works for people with moderate to severe plaque psoriasis in real-life settings in Italy. It follows patients who have already started the treatment to see how they are doing.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
This study provides continued access to the medication deucravacitinib for people who have completed one of several earlier studies. It aims to offer ongoing treatment for conditions like lupus, Sjogren's syndrome, or psoriasis.
This trial tests an oral medication called TQH3906 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve skin symptoms and is for adults who have not had enough success with other treatments.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.